{"id":108786,"date":"2020-06-17T10:22:19","date_gmt":"2020-06-17T17:22:19","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2020\/06\/regeneron-launches-trials-of-covid-19-antibody-cocktail"},"modified":"2020-06-17T10:22:19","modified_gmt":"2020-06-17T17:22:19","slug":"regeneron-launches-trials-of-covid-19-antibody-cocktail","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2020\/06\/regeneron-launches-trials-of-covid-19-antibody-cocktail","title":{"rendered":"Regeneron Launches Trials of COVID-19 Antibody \u201cCocktail\u201d"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/regeneron-launches-trials-of-covid-19-antibody-cocktail.jpg\"><\/a><\/p>\n<p>The cocktail, now named REGN-COV2, consists of two antibodies\u2014REGN10933 and REGN10987\u2014that are designed to bind non-competitively to the receptor binding domain of SARS-CoV-2\u2019s spike protein. Regeneron says that such binding diminishes the ability of mutant viruses to escape treatment\u2014with details from preclinical research to be published in upcoming research studies.<\/p>\n<hr>\n<p>Regeneron Pharmaceuticals said today it has launched the first clinical trial of its dual-antibody \u201ccocktail\u201d designed to both prevent and treat COVID-19, as well as prevent viral escape. The cocktail, now named REGN-COV2, consists of two antibodies\u2014REGN10933 and REGN10987\u2014that are designed to bind non-competitively to the receptor binding domain of SARS-CoV-2\u2019s spike protein. [Regeneron].<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The cocktail, now named REGN-COV2, consists of two antibodies\u2014REGN10933 and REGN10987\u2014that are designed to bind non-competitively to the receptor binding domain of SARS-CoV-2\u2019s spike protein. Regeneron says that such binding diminishes the ability of mutant viruses to escape treatment\u2014with details from preclinical research to be published in upcoming research studies. Regeneron Pharmaceuticals said today it [\u2026]<\/p>\n","protected":false},"author":534,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-108786","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/108786","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/534"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=108786"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/108786\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=108786"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=108786"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=108786"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}